Here's your news in US review and approval news in brief: AbbVie Inc. and Genentech Inc.'s Venclexta (venetoclax tablets) has become the seventh drug to score an approval under the FDA's Real-Time Oncology Review pilot for significant supplemental applications.
Several other companies reeled in supplemental approvals as well, including Regeneron Pharmaceuticals Inc.'s eye drug Eylea (aflibercept) for diabetic...








